SAP Depleter Dose Assessment Study in Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01406314 |
Recruitment Status :
Completed
First Posted : August 1, 2011
Last Update Posted : June 9, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Amyloidosis | Drug: GSK2315698 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 17 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | A Phase 1, Open Label, Dose Characteristic Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intravenous and Subcutaneous Doses of GSK2315698A in Patients With Systemic Amyloidosis |
Actual Study Start Date : | October 13, 2011 |
Actual Primary Completion Date : | November 14, 2012 |
Actual Study Completion Date : | November 14, 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: Intervention
Intravenous infusion for approximately 48 hours followed by subcutaneous injection
|
Drug: GSK2315698
Intravenous infusion for approximately 48hours followed by subcutaneous injection |
- Blood concentrations of SAP [ Time Frame: 19 weeks ]comparison of predicted vs observed
- Plasma concentrations of GSK2315698 [ Time Frame: 19 weeks ]changes in plasma concentrations of GSK2315698 over time
- safety and tolerability of GSK2315698 [ Time Frame: 19 weeks ]evaluated by adverse event (AE) reporting, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG).
- Change from baseline in blood SAP levels [ Time Frame: 19 weeks ]evaluate effect of GSK2315698 on SAP levels in the blood

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- medically diagnosed with systemic amyloidosis
- AST,ALT, alkaline phosphatase <= 3xULN and bilirubin ,1.5xULN
- undergone radio-labelled-SAP scanning as part of their routine clinical care
- male or female between 18 and 80 years of age inclusive, at time of signing the informed consent
- subject is ambulant and capable of attending CUC
- capable of giving written consent, which includes compliance with the requirements of the requirement and restrictions listed in the consent form
- a female subjects is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
- male subjects with female partners of child-bearing potential must agree to use contraception methods listed in the protocol and informed consent information. This must be followed from the time of the first dose of study medication to 85 days post-last dose.
- smokers (<10 cigarettes a day) are permitted but must be willing to abstain for the duration of residential study sessions
Exclusion Criteria:
- a positive pre-study Hepatitis B surface antigen or Hepatitis C antibody result within 3 months of screening
- the subject has participated in a clinical trial and has received an investigational therapeutic product (unlicensed) within 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing
- lactating females
- unwillingness or inability to follow the procedures outlined in the protocol
- subject is mentally or legally incapacitated
- renal failure requiring haemodialysis will normally result in exclusion. Subjects in patient group 4 on haemodyalysis may be considered providing their schedule of dialysis can be accommodated within the study schedule
- decompensated cardiac failure or recent history of syncope
- clinically significant anaemia - Hb<9g/dL
- use of prohibited medications
- poor or unsuitable venous access
- subjects with a QTc of > or equal to 480ms or other ECG abnormalities which, in the opinion of the investigator, is clinically significant in that they may increase safety risk
- uncontrolled hypertension with systolic BP> 170mm Hg and/or diastolic >100 mm Hg
- previous surgical procedures that result in altered anatomy of the upper digestive tract including cholecystectomy (gall bladder removal) will result in exclusion from the Entero-Test procedure, but the subject may still participate in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01406314
United Kingdom | |
GSK Investigational Site | |
Cambridge, United Kingdom, CB2 2GG |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT01406314 |
Other Study ID Numbers: |
114527 |
First Posted: | August 1, 2011 Key Record Dates |
Last Update Posted: | June 9, 2017 |
Last Verified: | June 2017 |
Phase 1 Patient Systemic Amyloidosis Amyloidosis |
Amyloidosis Proteostasis Deficiencies Metabolic Diseases |